EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients
- PMID: 16140919
- DOI: 10.1158/0008-5472.CAN-05-1705
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients
Abstract
To determine whether EGFR tyrosine kinase domain mutations are early events in the pathogenesis of lung adenocarcinomas, we tested for the presence of EGFR mutations in histologically normal bronchial and bronchiolar epithelia from lung adenocarcinomas bearing the common EGFR mutations. DNA was extracted from microdissected tissue obtained from 21 tumors with known EGFR mutations, 16 tumors without mutation, and 90 sites of normal bronchial and bronchiolar epithelium from the same surgical specimens. With the use of PCR and direct DNA sequencing, EGFR mutations identical to the tumors were detected in the normal respiratory epithelium in 9 of 21 (43%) patients with EGFR mutant adenocarcinomas but none in patients without mutation in the tumors. The finding of mutations being more frequent in normal epithelium within tumor (43%) than in adjacent sites (24%) suggests a localized field effect phenomenon. Our findings indicate that mutation of the tyrosine kinase domain of EGFR is an early event in the pathogenesis of lung adenocarcinomas, and suggest EGFR mutations as an early detection marker and chemoprevention target.
Similar articles
-
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.Cancer Genet Cytogenet. 2007 Mar;173(2):107-13. doi: 10.1016/j.cancergencyto.2006.10.007. Cancer Genet Cytogenet. 2007. PMID: 17321325
-
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Cancer Res. 2005 Mar 1;65(5):1642-6. doi: 10.1158/0008-5472.CAN-04-4235. Cancer Res. 2005. PMID: 15753357
-
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.Cancer Res. 2004 Dec 15;64(24):8919-23. doi: 10.1158/0008-5472.CAN-04-2818. Cancer Res. 2004. PMID: 15604253
-
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. doi: 10.1158/1078-0432.CCR-06-0555. Clin Cancer Res. 2006. PMID: 16857820 Review.
-
EGFR mutations and the terminal respiratory unit.Cancer Metastasis Rev. 2010 Mar;29(1):23-36. doi: 10.1007/s10555-010-9205-8. Cancer Metastasis Rev. 2010. PMID: 20135199 Review.
Cited by
-
Lung cancer.N Engl J Med. 2008 Sep 25;359(13):1367-80. doi: 10.1056/NEJMra0802714. N Engl J Med. 2008. PMID: 18815398 Free PMC article. Review. No abstract available.
-
Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293. J Pathol. 2014. PMID: 24307542 Free PMC article.
-
Activation of oncogenic pathways in idiopathic pulmonary fibrosis.Transl Oncol. 2014 Oct;7(5):650-5. doi: 10.1016/j.tranon.2014.05.002. Epub 2014 Jun 14. Transl Oncol. 2014. PMID: 24935008 Free PMC article.
-
Laricitrin suppresses increased benzo(a)pyrene-induced lung tumor-associated monocyte-derived dendritic cell cancer progression.Oncol Lett. 2016 Mar;11(3):1783-1790. doi: 10.3892/ol.2016.4153. Epub 2016 Jan 26. Oncol Lett. 2016. PMID: 26998077 Free PMC article.
-
Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.Mod Pathol. 2009 May;22(5):668-78. doi: 10.1038/modpathol.2009.19. Epub 2009 Mar 6. Mod Pathol. 2009. PMID: 19270647 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous